Drug may extend survival for men with advanced prostate cancer

January 29, 2014 by Serena Gordon, Healthday Reporter
Drug may extend survival for men with advanced prostate cancer
Study participants hadn't received any treatment with chemotherapy.

(HealthDay)—A new hormone therapy drug for men with prostate cancer may increase survival a bit and delay progression of the disease in men who have advanced prostate cancer that has been resistant to standard hormonal therapies, a new study suggests.

The study found that the enzalutamide increased survival by 29 percent and delayed by 81 percent in men who hadn't received any treatment with chemotherapy.

"There's new hope for men with very advanced prostate cancer," said study author Dr. Tomasz Beer, deputy director of the Knight Cancer Institute at Oregon Health and Science University in Portland. "This is a treatment with an excellent safety profile that can help men maintain quality of life and extend disease-free progression and extend survival."

The findings are scheduled to be presented Thursday at a meeting of the American Society of Clinical Oncologists, in San Francisco. The study authors reported receiving research funding from the drug's manufacturers.

The U.S. Food and Drug Administration approved enzalutamide in 2012 for use in men with advanced prostate cancer who have received chemotherapy. The drug is a type of hormone therapy called an androgen receptor blocker. Androgens are male hormones.

Enzalutamide is considered a second-generation hormone therapy. First-generation hormone therapy drugs for prostate cancer include bicalutamide, flutamide and nilutamide.

The current study included more than 1,700 men with prostate cancer that had spread to other areas of their bodies. The men's cancer also had progressed despite treatment with other types of hormone therapy. None of these men had yet been treated with chemotherapy. They had, however, been treated with surgery and radiation therapy.

Half of the volunteers were randomly assigned to receive enzalutamide and the other half received a placebo.

The study was stopped early because it was clear that enzalutamide offered a benefit over a placebo, so the drug was offered to all of the study volunteers.

"There was an 81 percent reduction in the risk of disease progression for men on enzalutamide," Beer said. "The median time to disease progression in placebo was [about four] months, but on the drug, a median time to disease progression hasn't been reached despite 20 months of follow-up."

When the study was stopped, 28 percent of those on enzalutamide had died, compared with 35 percent of those taking a placebo. The average median survival rate at the time of the first analysis was 32.4 months for those on enzalutamide versus 30.2 months for those taking a placebo.

"This drug is being used relatively early in prostate cancer, and patients can receive multiple treatments after," Beer said of the study population. Most of the men involved in the study were later treated with chemotherapy.

The drug is an oral medication, and it was well tolerated in the study. Previously published reports from when the drug was first approved suggested that the wholesale price of the medication would be about $7,450 a month.

"This drug is already FDA-approved in the post-chemotherapy setting, though it's not yet FDA-approved for use before chemotherapy," Beer said.

Dr. Ash Tewari, chairman of urology at the Icahn School of Medicine at Mount Sinai, in New York City, said enzalutamide works three different ways to suppress androgens, making it a "triple threat."

"This study's findings are exciting, and may give us another tool to fight this cancer," Tewari said. "And it was safe, with some minor side effects but nothing unusual."

Another study scheduled for presentation at the meeting looked at men with less advanced prostate cancer. This study found that adding radiation treatment to anti-androgen therapy dropped the 10- and 15-year prostate-cancer-specific death rate for men with locally advanced prostate cancer. Locally advanced prostate cancer is cancer that has grown through the prostate, but hasn't yet traveled to other areas of the body.

Surgery generally isn't an option for this type of cancer because it's difficult to remove all of the cancer cells.

The study, from Norwegian researchers, included 11 years of follow-up observation. Men who received hormone therapy alone had 10- and 15-year -specific death rates of 18.9 percent and 30.7 percent, respectively. The rates for men who received radiation and were significantly lower: 8.3 percent and 12.4 percent, respectively.

Because these studies were presented at a medical meeting, the data and conclusions should be viewed as preliminary until they are published in peer-reviewed journals.

Explore further: US approves radiation-based prostate cancer drug

More information: Learn more about prostate cancer from the American Cancer Society.

Related Stories

US approves radiation-based prostate cancer drug

May 15, 2013
(AP)—The U.S. Food and Drug Administration has approved a new injectable drug that uses radiation to treat advanced prostate cancer that has spread to the bones.

Golden age of prostate cancer treatment hailed as fourth drug in two years extends life

August 15, 2012
The head of one of the UK's leading cancer research organisations has hailed a golden age in prostate cancer drug discovery as for the fourth time in two years results are published finding a new drug can significantly extend ...

Enzalutamide adds five months survival in late-stage prostate cancer

August 16, 2012
Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.

Study shows benefits for men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy

December 6, 2013
Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to ...

FDA OKs expanded use of prostate cancer drug

December 10, 2012
(HealthDay)—The approved use of the drug Zytiga has been expanded to include treatment of men with late-stage, hormone therapy-resistant prostate cancer before they undergo chemotherapy, the U.S. Food and Drug Administration ...

Oral drug may improve survival in men with metastatic prostate cancer

November 19, 2013
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.